News

AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive, underdiagnosed cause of heart failure (HF). Diagnostic delays may increase cardiac…

AbstractBACKGROUND:Technetium-based cardiac amyloid radionuclide imaging enables noninvasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), but…

Long-term treatment with the experimental therapy candidate cliramitug safely and effectively reduces toxic clumps of the transthyretin (TTR) protein and heart…

Join this 30-minute Cardio Town Hall, moderated and led by Dr. Mazen Hanna and Dr. Mathew Maurer for an expert discussion on contemporary ATTR-CM clinical research…

AbstractBackgroundSodium glucose co-transporter 2 inhibitors (SGLT2i) improve outcomes in heart failure (HF), but evidence in transthyretin cardiac amyloidosis (…

AbstractBackgroundCardiac amyloidosis (CA) is increasingly recognized in clinical practice. Whether a guideline-based large language model can deliver clinician-…

As AstraZeneca exited the first quarter, initially skeptical analysts were coming around to the potential for the drugmaker to hit its goal of growing sales to $80…

Royalty Pharma has secured a stake in another transthyretin-mediated (ATTR) amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the…

AbstractBackground:Transthyretin (TTR) p.Ala45Thr variant is pathogenic, typically associated with cardiomyopathy and peripheral neuropathy. Leptomeningeal and…

AbstractIntroduction:Cardiac amyloidosis (CA) has been considered a rare disease. However, its prevalence is growing as healthcare practitioners have new, less…